Format

Send to

Choose Destination
Trends Cancer. 2017 May;3(5):319-325. doi: 10.1016/j.trecan.2017.03.011. Epub 2017 Apr 21.

Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?

Author information

1
Service d'Hématologie et Oncologie Pédiatrique, Hôpital pour Enfants de La Timone, Marseille, France; Inserm CRO2 UMR_S 911, Aix-Marseille University, Marseille, France; Metronomics Global Health Initiative, Marseille, France. Electronic address: nicolas.andre@ap-hm.fr.
2
Metronomics Global Health Initiative, Marseille, France; Laboratories for Tumor Aggressiveness and Stemness; National Institute of Cancer Research, National Health Research Institutes; College of Medicine, Taipei Medical University, Taiwan.
3
Inserm CRO2 UMR_S 911, Aix-Marseille University, Marseille, France.
4
Metronomics Global Health Initiative, Marseille, France; CNRS, INSERM, Aix-Marseille University, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille, France.

Abstract

Metronomic chemotherapy (MC) was initially described as an antiangiogenic therapy more than 15 years ago. Over the past few years, additional data have highlighted the impact of MC on the microenvironment beyond angiogenesis, with, most importantly, a potential impact on the immune system. Here, we review and reappraise the fact that MC might be able to directly kill cancer cells. Although long neglected, this question is of critical importance both fundamentally and clinically, especially when considering future associations with immunotherapies.

KEYWORDS:

angiogenesis; chemotherapy; immunity; metronomic chemotherapy; stem cells

PMID:
28718409
DOI:
10.1016/j.trecan.2017.03.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center